Drug Database
OM

omeprazole (Omez Insta)

✓ Approved

Dr.Reddy's Laboratories Ltd. · ATP4A · Small Molecule

What is omeprazole?

omeprazole is a small molecule developed by Dr.Reddy's Laboratories Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOmez Insta
CompanyDr.Reddy's Laboratories Ltd.
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Dr.Reddy's Laboratories Ltd.

Mechanism of Action

Molecular Targets

omeprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

omeprazole is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersGastritis✓ Approved

Related Research Articles

PubMedMedicine2026-07-25

Proton pump inhibitors use and the risk of osteoporosis and fractures: A two-sample Mendelian randomization study.

Li Ping P, Wu Ruiji R, Shi Hangchu H

The causal relationship between proton pump inhibitor (PPI) use and bone health outcomes remains uncertain. This study employs a Mendelian randomization (MR) approach to investigate the potential causal association between PPI use and the risk of osteoporosis and fractures. We selected 4 representative PPIs, including omeprazole, esomeprazole, lansoprazole, and rabeprazole, for our study. Bone health outcomes were evaluated through femoral neck bone mineral density (BMD), lumbar spine BMD, and the prevalence of osteoporosis and fracture across various anatomical sites, including the upper arm and shoulder, wrist and hand, lumbar spine and pelvis, femur, and lower leg and ankle. To evaluate PPI exposure and bone health outcomes, we utilized summary statistics derived from genome-wide association studies conducted in European ancestry populations. Primary causal estimates were derived using the inverse-variance weighting (IVW) approach, supplemented by MR-Egger, weighted median, and Mendelian Randomization Pleiotropy Residual Sum and Outlier methods. To strengthen the robustness of our findings, we conducted sensitivity analyses encompassing assessments of heterogeneity, horizontal pleiotropy, and leave-one-out analyses. Lansoprazole demonstrated a significant positive causal effect on femoral neck BMD (IVW: β = 0.137, 95% confidence interval: 0.063-0.210, P = 2.73E-04), whereas no statistically significant effects were observed for lansoprazole on lumbar spine BMD, osteoporosis, or fracture risk. Esomeprazole showed a marginal causal association with an elevated risk of femur fracture (IVW: odds ratio = 1.049, 95% confidence interval: 1.004-1.096, P = .031); however, this association lost statistical significance following Bonferroni correction. Its effects on BMD, osteoporosis, and fractures at other anatomical sites remained nonsignificant. No causal associations with BMD, osteoporosis, or fracture risk were identified for either omeprazole or rabeprazole. Sensitivity analyses further reinforced the robustness and reliability of these findings. This MR analysis found no compelling evidence to support a causal association between PPI use and the risk of osteoporosis or fractures.

PMID 42499118
Read full article →
PubMedCurrent computer-aided drug design2026-07-22

Exploring Omeprazole Effect on Pro-apoptotic Factors in Colorectal Cancer Treatment: Insights from In Silico Studies and Antiproliferative Assessment on HT29 Cells.

Abdizadeh Tooba T, Banisakin Sana S, Samani Keyhan Ghatreh KG, Salehi-Vanani Najmeh N et al.

Colorectal Cancer (CRC) is one of the most common cancers worldwide. There is an urgent need to identify new drugs for CRC treatment. The apoptotic factors Bad, Bid, Bik, Bim, Bax, and Bak play a crucial role in activating the apoptotic cascade pathways. Inhibition of these factors is a main strategy of cancer therapy. This study investigates the effects of omeprazole on pro-apoptotic factors (Bak, Bad, Bim, Bik, Bid, and Bax) involved in the apoptosis induction in CRC using both in-silico and in-vitro techniques. The 3D structure of omeprazole was docked to pro-apoptotic factors obtained from the Protein Data Bank (PDB) using Autodock 4.2.6 software. Molecular Dynamics (MD) simulations were also carried out with GROMACS 2022 to validate the stability of the ligandreceptor complexes. Additionally, an in-vitro experiment was performed to evaluate the cytotoxicity of omeprazole on the HT-29 cell line using the MTT assay. The strong binding affinity between omeprazole and pro-apoptotic factors was observed in molecular docking, with binding energies less than -5.0 kcal/mol. The stability of the omeprazole-receptor complexes was confirmed through MD simulations. Moreover, in vitro results indicated that omeprazole can inhibit the growth and proliferation of colorectal cancer cells with an IC50 value of 400 μM. In silico studies presented that omeprazole could affect pro-apoptotic factors responsible for inducing apoptotic pathways. The in vitro studies assume that omeprazole has significant cytotoxic activity against colorectal cancer cell lines. These results demonstrated the therapeutic effects of omeprazole by inducing apoptosis in colorectal cancer through the influence of pro-apoptotic factors, and it appears that omeprazole could be a promising drug repurposing candidate for the treatment of colorectal cancer.

PMID 42483915
Read full article →
PubMedJournal of ethnopharmacology2026-07-21

Gastroprotective effect of Daphniphyllum calycinum Benth.-Polygonum hydropiper L. against gastric mucosal injury through autophagy activation and apoptosis suppression.

Zhi Yunyun Y, Ou Jiayi J, Wu Dexin D, Zhou Keli K et al.

Gastric mucosal injury, commonly induced by ethanol and psychological stress, represents a significant clinical challenge with limited natural therapeutic options. The Li ethnic herbal pair consisting of Daphniphyllum calycinum Benth. and Polygonum hydropiper L. (DCPH), commercially available as Fengliao Changweikang Granules, is traditionally used by the Li people of Hainan, China, for gastrointestinal disorders. However, its gastroprotective effects and underlying mechanisms remain to be systematically characterized. This study aimed to investigate the protective effects of DCPH and its functional associations with autophagy and apoptosis pathways in ethanol-induced gastric mucosal injury models. The chemical profile of DCPH-containing serum was analyzed using HPLC-MS. Network pharmacology and molecular docking were performed to predict candidate components and putative protein interaction partners. Protective effects were evaluated in ethanol-induced gastric injury models in KM mice and human gastric epithelial GES-1 cells. Gastric mucosal morphology, ulcer index, histopathology (H&E staining), apoptosis (TUNEL, flow cytometry), and autophagy markers (Beclin1, LC3-II/I, P62) were assessed. Transcriptomic and metabolomic analyses were conducted to explore regulatory pathways. HPLC-MS identified 86 compounds in DCPH-containing serum, including flavonoids and alkaloids. Molecular docking revealed predicted strong binding affinities (<-7.0 kcal/mol) between key components (quercetin, kaempferol, caldaphnidine C) and apoptosis/autophagy-related proteins (BAX, Bcl-2, CASP3, Beclin1, LC3, P62), suggesting potential interactions that warrant further experimental validation. In vivo, DCPH significantly reduced gastric mucosal congestion, edema, and ulcer index, with the high-dose effect comparable to omeprazole. DCPH treatment was associated with upregulated Beclin1 and LC3-II/I and downregulated P62; these effects were partially reversed by chloroquine. DCPH treatment was also associated with reduced apoptosis, coinciding with modulation of BAX/Bcl-2/Cleaved Caspase-3 expression. Integrated omics analyses indicated regulation of lipid metabolism, glycolysis, and inflammatory pathways. DCPH demonstrates protective effects against ethanol-induced gastric mucosal damage that are functionally associated with modulation of autophagy markers and apoptosis-related proteins. These findings support further investigation into the traditional use of this herbal pair and its potential as a natural therapeutic candidate, pending clinical validation and direct target confirmation.

PMID 42476203
Read full article →
PubMedSemergen2026-07-19

[Appropriateness of active proton pump inhibitor prescription in a rural health center: a quasi-experimental study in Aragon, Spain (2024-2025)].

Paúles-Cuesta I M IM, Guiu-Campos M M, Güerre-Oto M N MN

To evaluate the impact of a proton pump inhibitor (PPI) prescription review and optimization program in patients ≥65 years of age treated at the Caspe health center (Aragon, Spain). A prospective, observational, quasi-experimental study was conducted between June 2024 and December 2025 in a rural primary care area (n=12,081 inhabitants). Patients ≥65 years of age with active PPI prescriptions were included. The STOPP/START criteria were applied to identify potentially inappropriate prescriptions, and deprescribing or substitution with omeprazole was promoted based on efficiency and clinical appropriateness criteria. In each period, 7,623 and 7,734 patients with active PPI prescriptions were evaluated, of whom 2,456 and 2,222 were ≥65 years old. The application of the STOPP/START criteria increased from 8.6% to 44.1%, meeting quality standards. Discontinuation of PPIs without indication increased from 0.12% to 0.79%, showing a favorable trend due to the low baseline prevalence. The substitution of non-omeprazole PPIs with omeprazole showed a slight increase (from 0.41% to 0.47%), but did not reach the target level. The systematic implementation of STOPP/START criteria in rural primary care is an effective strategy to improve the appropriateness of PPI prescribing in the elderly population, promoting a more rational and efficient use of resources. The results suggest that these interventions are replicable in other rural settings, although the substitution of more expensive drugs requires coordination between levels of care and additional implementation strategies.

PMID 42470782
Read full article →
PubMedJournal of the American Veterinary Medical Association2026-07-16

Cumulative omeprazole administration is associated with increased hazard of exercise-induced pulmonary hemorrhage detection in Thoroughbred racehorses.

Jones Olivia J OJ, Ahern Benjamin J BJ, Stewart Brian D BD, Morton John M JM et al.

To evaluate associations between cumulative oral omeprazole administration and the occurrence of exercise-induced pulmonary hemorrhage (EIPH), epistaxis, atrial fibrillation, and fracture in Thoroughbred racehorses. A retrospective cohort study of 2,924 Thoroughbred racehorses in training in Hong Kong during the 2012-2013 and 2022-2023 racing seasons was performed with veterinary, training, and racing records. Time-to-event analyses were performed with Cox proportional hazards models, with cumulative omeprazole dose fitted as a time-varying covariate and adjustment for trainer, recent training intensity, racing year, and age at first trackwork. Cumulative omeprazole administration during the preceding 30 days was associated with an increased hazard of EIPH detection (hazard ratio, 1.08 for each 10-g increase; 95% CI, 1.01 to 1.15). A similar direction of association was observed for epistaxis (hazard ratio, 1.20; 95% CI, 0.99 to 1.45). Effect estimates were close to null for associations between cumulative omeprazole administration and fracture (hazard ratio, 1.02 for each 10-g increase over 60 days; 95% CI, 0.89 to 1.17) or atrial fibrillation (hazard ratio, 1.02 for each 10-g increase over 30 days; 95% CI, 0.86 to 1.20). Recent cumulative omeprazole administration was not associated with fracture or atrial fibrillation in this population of Thoroughbred racehorses. However, recent omeprazole administration was associated with an increased hazard of EIPH detection. These findings supported careful consideration of the indication and duration of omeprazole administration in racehorses, particularly when administered prophylactically.

PMID 42456746
Read full article →
PubMedInternational journal of molecular sciences2026-07-15

Evaluation of the Molecular Docking of Potential Targets and the Time-Dependent Myocardial Effects of Omeprazole in Normotensive and Spontaneously Hypertensive Rats Subjected to Cardiac Ischemia and Reperfusion.

de Aquino Filho Geraldo Teotônio GT, Felisberto Oliveira Alex Sandro AS, de Araújo Erisvaldo Amarante EA, da Silva Yamamoto Joyce Umbelino JU et al.

Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders and are generally considered safe for short-term use. However, increasing experimental and clinical evidence suggests potential cardiovascular effects associated with chronic exposure, possibly related to endothelial dysfunction and impaired nitric oxide bioavailability. Therefore, we decided to investigate whether the cardiovascular effects of omeprazole are dependent on the timing of administration in a model of cardiac ischemia-reperfusion (CIR) in normotensive Wistar rats (NWR) and spontaneously hypertensive rats (SHR). Twelve- to sixteen-week-old male NWR and SHR were allocated into four groups: (1) SHAM: NWR and SHR were submitted to surgery with no ischemia; (2) (SS + CIR): NWR and SHR were treated with a 0.9% saline solution and submitted to CIR; and (3) (OME + ISQ): NWR and SHR were treated with 10 mg/kg i.v. omeprazole (OME) before cardiac ischemia and submitted to CIR or (4) after cardiac ischemia but before cardiac reperfusion (ISQ + OME). Electrocardiograms were monitored to assess ventricular arrhythmias (VA), atrioventricular block (AVB), and lethality (LET). Serum creatine kinase-MB (CK-MB) levels were quantified, and histopathological analyses were performed to evaluate the degree of myocardial injury in the different study groups. Administration of OME prior to cardiac ischemia increased the incidence of VA, AVB, LET, and serum CK-MB levels in both NWR and SHR. In contrast, administration before cardiac reperfusion did not exacerbate cardiac injury and was associated with the attenuation of electrophysiological instability. Histopathological findings corroborated the biochemical and functional outcomes. OME, when administered prior to cardiac ischemia, worsens both cardiac arrhythmias and myocardial injury; however, administration immediately prior to cardiac reperfusion does not increase cardiac arrhythmias and decreases myocardial injury in both NWR and SHR.

PMID 42450192
Read full article →

+9668 more articles available with a free account

Sign up free to view all articles →

Ask about omeprazole